NCT01887847View on ClinicalTrials.gov

Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Nicotine Pharmacokinetic Study
Interventions
DRUG

Nicotine (Pharmaceutical Productions Inc.)

An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.

DRUG

Nicotine (Pharmaceutical Productions Inc.)

A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.

Trial Locations (1)

90502

Friends Research Institute Clinic, Torrance

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Pharmaceutical Productions Inc.

INDUSTRY